A reterospective study assessing the inferior outcomes in minority patients with unresectable non-small cell lung cancer (NSCLC) After Durvalumab consolidation therapy
Latest Information Update: 13 Oct 2021
At a glance
- Drugs Durvalumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 13 Oct 2021 New trial record
- 14 Sep 2021 Results presented at the 2021 World Conference on Lung Cancer